Science Explorer Back to mapMap
Discussion
Topic · Pathology and Forensic Medicine

Breast Lesions and Carcinomas

Breast Lesions and Carcinomas is a research topic within Pathology and Forensic Medicine. Science Explorer counts 29k research works in it since 1950. 10.2% of them reached the world's top 10% most cited for their field and year.

This cluster of papers covers advancements in breast pathology, imaging techniques, and diagnostic procedures. It includes topics such as breast cancer screening, mammography, ultrasound, histological analysis of breast lesions, and the management of specific breast conditions like metaplastic carcinoma and phyllodes tumors.

  • Breast Cancer
  • Mammography
  • Ultrasound
  • Pathology
  • Lesions
  • Biopsy
  • Metaplastic Carcinoma
  • Phyllodes Tumors
  • Atypical Hyperplasia
  • Granulomatous Mastitis
Research works
29k
fractional, since 1950
In the world top 10%
2.9k
per year above
Top-10% rate
10.2%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+5%
the tick is no change
Largest producer
United States
28% of the 10 largest, 2022-now
Breast Lesions and Carcinomas

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Breast Lesions and Carcinomas research?

By volume, the United States and China publish the most (1.1k and 932 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.1k works
  2. 2 China 932 works
  3. 3 India 481 works
  4. 4 United Kingdom 266 works
  5. 5 Japan 232 works
  6. 6 Türkiye 192 works
  7. 7 Italy 186 works
  8. 8 South Korea 166 works
  9. 9 Germany 144 works
  10. 10 Spain 123 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 28.1%China: 24.6%India: 12.7%United Kingdom: 7.0%6 others listed: 27.6%28%largest
United States1,064 · 28.1%China932 · 24.6%India481 · 12.7%United Kingdom266 · 7.0%6 others listed1,044 · 27.6%

Shares of the rows listed above, not of the whole node.

Which institutions lead Breast Lesions and Carcinomas research?

By volume in 2022-now, Harvard University publishes the most Breast Lesions and Carcinomas research, followed by All India Institute of Medical Sciences and Mayo Clinic.

By volume, 2022-now

  1. 1 Harvard UniversityUnited States 53 works
  2. 2 All India Institute of Medical SciencesIndia 47 works
  3. 3 Mayo ClinicUnited States 40 works
  4. 4 The University of Texas MD Anderson Cancer CenterUnited States 40 works
  5. 5 Memorial Sloan Kettering Cancer CenterUnited States 40 works
  6. 6 Shanghai Jiao Tong UniversityChina 32 works
  7. 7 Sun Yat-sen UniversityChina 31 works
  8. 8 Sichuan UniversityChina 27 works
  9. 9 Sungkyunkwan UniversitySouth Korea 26 works
  10. 10 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 24 works

Who are the leading researchers in Breast Lesions and Carcinomas?

The most-cited researchers publishing on Breast Lesions and Carcinomas include Ahmedin Jemal, Freddie Bray and Walter Churchill Willett.

  1. 1 Ahmedin Jemal United States 761k citations
  2. 2 Freddie Bray France 550k citations
  3. 3 Walter Churchill Willett United States 411k citations
  4. 4 Elaine R. Mardis United States 346k citations
  5. 5 Hermann Brenner Germany 343k citations
  6. 6 Jun Wang China 340k citations
  7. 7 Peter Christian Gøtzsche Denmark 292k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Breast Lesions and Carcinomas?

The most cited paper in Breast Lesions and Carcinomas is "Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer" (Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al., 2013), with 13,212 citations. Next come "A Gene-Expression Signature as a Predictor of Survival in Breast Cancer" (6,562) and "A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer" (6,414).

Most cited papers
#PaperReleasedCitations
1 Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer Reiki Nishimura, Tomofumi Osako, Yasuyuki Nishiyama et al. · Oncology Open access 2013 13,212
2 A Gene-Expression Signature as a Predictor of Survival in Breast Cancer Marc J. van de Vijver et al. · New England Journal of Medicine Open access 18 Dec 2002 6,562
3 A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer Soonmyung Paik, Steven Shak, Gong Tang et al. · New England Journal of Medicine Open access 10 Dec 2004 6,414
4 Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer Bernard Fisher, Stewart Anderson, John Bryant et al. · New England Journal of Medicine Open access 16 Oct 2002 6,293
5 pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up C.W. Elston, Ian Ogilvie Ellis · Histopathology Nov 1991 6,254
All 100 most cited papers, with filters and sorting

Where is Breast Lesions and Carcinomas research done?

The largest centres of Breast Lesions and Carcinomas research in 2022-now are Beijing (China), Seoul (South Korea), New York (United States) and Shanghai (China).

Largest cities, 2022-now

  1. 1 BeijingChina 103 works
  2. 2 SeoulSouth Korea 96 works
  3. 3 New YorkUnited States 85 works
  4. 4 ShanghaiChina 84 works
  5. 5 IstanbulTürkiye 70 works
  6. 6 LondonUnited Kingdom 65 works
  7. 7 GuangzhouChina 63 works
  8. 8 TokyoJapan 57 works
  9. 9 New DelhiIndia 56 works
  10. 10 HoustonUnited States 55 works
See Breast Lesions and Carcinomas on the map

Where is the best place to study Breast Lesions and Carcinomas?

Among universities, judged by research, Humanitas University, Harvard University and Harbin Medical University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 21.33%fractional works in this field (log) →share of work in the world top 10% →Karolinska InstitutetHarbin Medical Unive…Humanitas UniversityHarvard University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Humanitas UniversityItaly 70.631.0%15.5×11 +121.9%
2Harvard UniversityUnited States 65.417.9%3.5×52 -32.7%
3Harbin Medical UniversityChina 64.032.2%9.8×16 +42.7%
4Karolinska InstitutetSweden 63.734.5%3.7×10 +10.2%
5Sungkyunkwan UniversitySouth Korea 63.020.9%8.0×26 +29.8%
6Seoul National UniversitySouth Korea 60.018.8%4.2×23 +47.1%
7Sichuan UniversityChina 54.016.1%2.5×27 +43.3%
8Università Cattolica del Sacro CuoreItaly 53.020.5%7.2×15 +76.2%
9All India Institute of Medical SciencesIndia 51.32.9%8.9×47 +42.4%
10Duke UniversityUnited States 51.318.5%3.4×13 +46.2%

Universities only. The score blends excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Breast Lesions and Carcinomas, country by country

Is Breast Lesions and Carcinomas research growing?

Output in 2022-2025 was 5% higher than in 2018-2021, peaking in 2025. The fastest-growing topics are Breast Lesions and Carcinomas.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Breast Lesions and Carcinomas as a percentage of every work published that year, 0.020% in 2024.

still counting0.020%0.040%Breast Lesions and Carcinomas0.022% in 202519801990200020102020

Fractional works of Breast Lesions and Carcinomas over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Breast Lesions and Carcinomas10.1% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Breast Lesions and Carcinomas. Posts are plain text and can be reported.